Physical and functional well-being and symptoms of ovarian cancer in women undergoing first-line of chemotherapy: a one-year follow-up

被引:3
作者
Ferracini, Amanda Canato [1 ]
Pereira, Gabriela [2 ]
de Souza, Cinthia Madeira [3 ]
dos Santos, Thiago Fortes Cabello [4 ]
Sarian, Luis Otavio [5 ]
Derchain, Sophie [5 ]
Mazzola, Priscila Gava [6 ]
机构
[1] Univ Estadual Campinas, Grad Program Med Sci, Fac Med Sci, Sch Med Sci, 126 Tessalia Vieira de Camargo, BR-13083887 Campinas, SP, Brazil
[2] Univ Estadual Campinas, Fac Pharmaceut Sci, Grad Program Pharmaceut Sci, 200 Candido Portinari, BR-13083871 Campinas, SP, Brazil
[3] Univ Estadual Campinas, Sch Med Sci, Grad Program Gerontol, 126 Tessalia Vieira de Camargo, BR-13083887 Campinas, SP, Brazil
[4] Pontifical Catholic Univ Campinas, Ctr Life Sci, Fac Med, BR-13034685 Campinas, SP, Brazil
[5] Univ Estadual Campinas, Sch Med Sci, Dept Obstet & Gynecol, 126 Tessalia Vieira de Camargo, BR-13083887 Campinas, SP, Brazil
[6] Univ Estadual Campinas, Fac Pharmaceut Sci, 200 Candido Portinari, BR-13083871 Campinas, SP, Brazil
基金
巴西圣保罗研究基金会;
关键词
Chemotherapy; Quality of life; Physical; Function; Ovarian cancer; QUALITY-OF-LIFE; NEOADJUVANT CHEMOTHERAPY; SURVIVORS; SURGERY; TRAJECTORIES; CARBOPLATIN; PACLITAXEL; DISTRESS; OUTCOMES; PHASE-3;
D O I
10.1007/s00520-021-06298-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Clinicopathological features and chemotherapy can influence the quality of life (QOL), women with ovarian cancer. This study aimed to evaluate the physical and functional well-being, and ovarian cancer-specific effects scores reported from QOL questionnaire among women with ovarian cancer at the time of in their initial diagnosis and access the scores trajectory of women receiving neoadjuvant and adjuvant chemotherapy. Methods This prospective study used cross-sectional analysis at baseline and longitudinal analysis from baseline to 12-month post-chemotherapy. QOL was evaluated at the baseline, at sixth cycle and 12-month post-chemotherapy using FACT-O questionnaire. Clinicopathological features and chemotherapy regime were evaluated and tested for associations with QOL measures. Results Of the 38 women enrolled in this study, 27 (80.1%) completed the questionnaire for 12 months. The multivariate linear regression results suggest, at the baseline, women with advance stage and presence of post-surgery residual disease showed lower scores in physical and functional well-being, ovarian cancer-specific effects, and FACT-O TOI domains (p < 0.05). Longitudinal analysis spanning over 12 months showed an improvement in mean physical well-being, functional well-being, and ovarian cancer-specific effects scores, independent of chemotherapy received (p < 0.05). Conclusions At the baseline, the clinicopathological features such as stage, presence of post-surgery residual disease, and type of chemotherapy correlated with on QOL scores. At one-year follow-up, women who underwent chemotherapy showed improvement in QOL regardless of the type of chemotherapy they received. Future prospective study with a larger group is recommended.
引用
收藏
页码:7421 / 7430
页数:10
相关论文
共 43 条
[1]   Ovarian cancer survivors' quality of life: a systematic review [J].
Ahmed-Lecheheb, D. ;
Joly, F. .
JOURNAL OF CANCER SURVIVORSHIP, 2016, 10 (05) :789-801
[2]   Reliability and validity of the functional assessment of cancer therapy-ovarian [J].
Basen-Engquist, K ;
Bodurka-Bevers, D ;
Fitzgerad, MA ;
Webster, K ;
Cella, D ;
Hu, SH ;
Gershenson, DM .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (06) :1809-1817
[3]   When will I feel normal again? Trajectories and predictors of persistent symptoms and poor wellbeing after primary chemotherapy for ovarian cancer [J].
Beesley, Vanessa L. ;
Webber, Kate ;
Nagle, Christina M. ;
DeFazio, Anna ;
Obermair, Andreas ;
Williams, Merran ;
Friedlander, Michael ;
Webb, Penelope M. .
GYNECOLOGIC ONCOLOGY, 2020, 159 (01) :179-186
[4]   Changes in supportive care needs after first-line treatment for ovarian cancer: identifying care priorities and risk factors for future unmet needs [J].
Beesley, Vanessa L. ;
Price, Melanie A. ;
Webb, Penelope M. ;
O'Rourke, Peter ;
Marquart, Louise ;
Butow, Phyllis N. .
PSYCHO-ONCOLOGY, 2013, 22 (07) :1565-1571
[5]  
Blagden SP, 2020, LANCET ONCOL, V21, P969, DOI 10.1016/S1470-2045(20)30218-7
[6]   Course of chemotherapy-induced peripheral neuropathy and its impact on health-related quality of life among ovarian cancer patients: A longitudinal study [J].
Bonhof, Cynthia S. ;
Mols, Floortje ;
Vos, M. Caroline ;
Pijnenborg, Johanna M. A. ;
Boll, Dorry ;
Vreugdenhil, Gerard ;
Ezendam, Nicole P. M. ;
van de Poll-Franse, Lonneke V. .
GYNECOLOGIC ONCOLOGY, 2018, 149 (03) :455-463
[7]   Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer [J].
Chan, J. K. ;
Brady, M. F. ;
Penson, R. T. ;
Huang, H. ;
Birrer, M. J. ;
Walker, J. L. ;
DiSilvestro, P. A. ;
Rubin, S. C. ;
Martin, L. P. ;
Davidson, S. A. ;
Huh, W. K. ;
O'Malley, D. M. ;
Boente, M. P. ;
Michael, H. ;
Monk, B. J. .
NEW ENGLAND JOURNAL OF MEDICINE, 2016, 374 (08) :738-748
[8]   Quality of life in women treated with neoadjuvant chemotherapy for advanced ovarian cancer: A prospective longitudinal study [J].
Chan, YM ;
Ng, TY ;
Ngan, HYS ;
Wong, LC .
GYNECOLOGIC ONCOLOGY, 2003, 88 (01) :9-16
[9]  
Chase DM, 2011, EXPERT REV PHARM OUT, V11, P421, DOI [10.1586/erp.11.41, 10.1586/ERP.11.41]
[10]   Functional loss in daily activity in ovarian cancer patients undergoing chemotherapy [J].
Cheong, In Yae ;
Yoo, Ji Sung ;
Chung, Seung Hyun ;
Park, Sang Yoon ;
Song, Hyun-Ju ;
Lee, Jeong-Won ;
Hwang, Ji Hye .
ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2019, 299 (04) :1063-1069